Ticasse 1000 mg

Form: Tablets
Dosage: 1000mg
Packaging: 14 film-coated tablets

Active substance: amoxicillin – clavulanic acid

Form: film-coated tablet

Dosage per tablet: 875 mg amoxicillin + 125 mg clavulanic acid


– Ticasse 1000 mg: Box of 14 film-coated tablets

– Dafraclav 1000 mg: Box of 10 film-coated tablets

Target: adults

Ticasse / Dafraclav 1000mg is a bactericidal antibiotic

– Amoxicillin rapidly kills susceptible bacteria

– Clavulanic acid prevents the inactivation of amoxicillin by enzymes produced by bacteria.

Ticasse/Dafraclav is indicated for the treatment of the following infections

  • Infections of the upper respiratory tract
    • Otitis media / sinusitis / tonsillitis / pharyngitis / laryngitis
  • Infections of the lower respiratory tract
    • Chronic bronchitis (superinfection), community acquired pneumonia
  • Skin and soft tissue infections
    • Cellulitis, animal bites
    • Dental abscesses
    • Abscesses, boils, wounds, acnes superinfections
  • Urinary tract infections
    • Cystitis, pyelonephritis
  • Bone and joint infections

The usual dose: 1 tablet of Ticasse/Dafraclav 1000 mg every 12 hours.

Ticasse/Dafraclav 1000 mg has been specially developed to allow a dosage of 2 doses per day (every 12 hours).

For some more severe infections the dosage can be increased to 3 doses per day (every 8 hours).

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma